Genentech

Genentech has made four vice president appointments: William N. Anderson to vice president, Sales and Marketing, Immunology; Scott Carmer to vice president, Sales and Marketing, Rituxan Immunology; Pamela M. Klein, M.D., to vice president, Clinical Oncology, Hematology and HER Family; and Mary B. Sliwkowski, Ph.D., to vice president, Regulatory Affairs, Chemistry Manufacturing and Controls.

Mr. Anderson will be responsible for leading the sales and marketing activities for Raptiva, Xolair, Rituxan Immunology and the Immunology pipeline products. He joins the company from Biogen Idec, where he held several leadership positions, including vice president and general manager of the Neurology Business Unit. Prior, Mr. Anderson was Biogen’s vice president of Finance, Business Planning.

Mr. Carmer joins Genentech in the newly created position of vice president, Sales and Marketing, Rituxan Immunology. In this role, he will be responsible for sales and marketing of Rituxan for immunological disorders, and for the commercialization of new products for immunology from Genentech’s B-cell portfolio. He joins the company from Amgen, where he most recently served as Global Therapeutic Area Head of the Global Inflammatory Disorders group. Prior, he was Amgen’s senior director of Aranesp Marketing. Before joining Amgen, Carmer held various roles in the U.S. and in the UK with GlaxoSmithKline’s sales and marketing and business development groups.

Dr. Klein has been promoted to the newly created position of vice president, Clinical Oncology, Hematology and HER Family. She is responsible for the HER Family/B-cell oncology clinical science programs, currently consisting of Herceptin, Tarceva, and Rituxan. In this role, Dr. Klein oversees the Clinical Science and Medical Science Liaison groups and will continue to chair the Development Review Committee for all HER Family/B-cell activities. Klein joined Genentech in 2001 from the National Cancer Institute (NCI) in Bethesda, Maryland, where she was Research Director of the NCI-Navy Breast Care Center.

Dr. Sliwkowski has been promoted to the newly created position of vice president, Regulatory Affairs, Chemistry Manufacturing and Controls (CMC). She will be responsible for all regulatory aspects of CMC, including the filings of BLAs, NDAs and INDs, as well as regulatory submissions for CMO operations. Dr. Sliwkowski and her group will maintain constant FDA interactions, set internal regulatory strategies and facilitate FDA facility approvals. She joined Genentech in 1985 as a scientist in Process Sciences and held positions of increasing responsibility, including director, Analytical Chemistry Department, Process Sciences; senior director, Quality Control Department; acting head, Global Quality; and, most recently, senior director, Regulatory Affairs, Product Manufacturing and Regulatory Submissions Operations.